Efficacy of inactivated poliovirus vaccine in India

Hamid Jafari(World Health Organization - India), Jagadish M. Deshpande(Haffkine Institute), Roland W. Sutter(World Health Organization), Sunil Bahl(World Health Organization - India), Harish Verma(World Health Organization), M. Ridwan Said Ahmad(World Health Organization - India), Abhishek Kunwar(World Health Organization - India), Rakesh Vishwakarma(World Health Organization - India), Ashutosh Agarwal(World Health Organization - India), Shilpi Jain(Panacea Biotec (India)), Concepción F. Estívariz(Centers for Disease Control and Prevention), Raman Sethi(World Health Organization - India), Natalie A. Molodecky(World Health Organization), Nicholas C. Grassly(Imperial College London), Mark A. Pallansch(Centers for Disease Control and Prevention), Arani Chatterjee(Panacea Biotec (India)), R. Bruce Aylward(World Health Organization)
Science
August 21, 2014
Cited by 113Open Access
Full Text

Abstract

Inactivated poliovirus vaccine (IPV) is efficacious against paralytic disease, but its effect on mucosal immunity is debated. We assessed the efficacy of IPV in boosting mucosal immunity. Participants received IPV, bivalent 1 and 3 oral poliovirus vaccine (bOPV), or no vaccine. A bOPV challenge was administered 4 weeks later, and excretion was assessed 3, 7, and 14 days later. Nine hundred and fifty-four participants completed the study. Any fecal shedding of poliovirus type 1 was 8.8, 9.1, and 13.5% in the IPV group and 14.4, 24.1, and 52.4% in the control group by 6- to 11-month, 5-year, and 10-year groups, respectively (IPV versus control: Fisher's exact test P < 0.001). IPV reduced excretion for poliovirus types 1 and 3 between 38.9 and 74.2% and 52.8 and 75.7%, respectively. Thus, IPV in OPV-vaccinated individuals boosts intestinal mucosal immunity.


Related Papers

No related papers found

Powered by citation graph analysis